Cargando…
Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples
OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with surgery or chemotherapy. Programmed death ligand 1 expression (PD-L1) immunotherapy has been successful for treating lung and other cancers with PD-L1 expression. However, in many unresectable PDAC cases, cytological sampl...
Autores principales: | Muggilli, Michael, Russell, Donna, Zhou, Zhongren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Scientific Scholar
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645468/ https://www.ncbi.nlm.nih.gov/pubmed/34876919 http://dx.doi.org/10.25259/Cytojournal_78_2020 |
Ejemplares similares
-
Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens
por: Xu, Huihong, et al.
Publicado: (2018) -
Automated Immunostaining Platform in Cytology
por: Sharma, Shelly, et al.
Publicado: (2021) -
Cell-to-cell interaction analysis of prognostic ligand-receptor pairs in human pancreatic ductal adenocarcinoma
por: Suzuki, Sayaka R., et al.
Publicado: (2021) -
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
por: Satoi, Sohei
Publicado: (2021) -
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
por: Wei, Kongyuan, et al.
Publicado: (2021)